Rotigotine Effect on Nocturnal Hypokinesia Compares to Placebo Control: A Quantitative Assessment by Wearable Sensors

Parkinson's disease (PD) is the neurodegenerative disease which is caused by Lewy bodies deposition in central and peripheral nervous system. The mains symptoms include both motor and non motor symptoms such as bradykinesia, rigidity, rest tremor, postural instability, autonomic dysfunction or neuropsychiatric symptoms. Moreover, the PD symptoms not only occur in the daytime, but also in the nighttime. The nighttime symptoms or nocturnal symptoms can make the patients disabling as well as the daytime symptoms. The bradykinesia that occurs in the nighttime is called nocturnal hypokinesia which also make many serious consequences such as bedsore, falling or aspiration or death.

In this study, the investigators aim to study the effects of rotigotine transdermal patch compare to placebo on mainly the aspect of nocturnal hypokinesia.

Study Overview

• Status: Unknown
• Conditions: Nocturnal Hypokinesia
• Intervention / Treatment: Drug: Rotigotine; Drug: Placebo

Detailed Description

The investigators recruited PD patients who had history of nocturnal hypokinesia and randomized by running number (blind) into 2 groups including active and placebo group. Baseline demographic, disease characteristics, nocturnal questionnaires and wearable nocturnal sensors data were collected before drug titration. In active group, participants received the rotigotine transdermal patch titration from 2 mg/day to maximum dosage which participants had no side effect or 16 mg/ day every week. In placebo group, participants would get the placebo patch titration as the active group. After participants got maintenance dosage, participants would get the physical examination, nocturnal questionnaires and wearable nocturnal sensors as before study.

• Study Type: Interventional
• Enrollment (Anticipated): 40
• Phase: Phase 4

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

• Patients: PD patients (age ≥ 18 years) who have history of nocturnal hypokinesia
• Patients not taking levodopa were eligible for study
• Patients who taking immediate- released levodopa,they had been on a stable dose for 28 days prior to baseline assessment and during the study
• Patients did not use control-released L-dopa at bedtime

Exclusion Criteria:

• History of narcolepsy, excessive daytime sleepiness, sudden onset of sleep
• History of hallucination, dementia and psychosis
• Evidence of ICDs
• Clinical relevant to cardiovascular disorders (including prolonged QTc ≥ 500 ms, recent MI)
• History of seizure or stroke in the past 1 year
• Patients had participated in other clinical trial in the past 28 days

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Quadruple

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Active Comparator: Patient (active) group; Rotigotine titration up to 16 mg/24 hr; Starting dose 2 mg/24 hr up titrate 2 mg weekly to optimal/maximum dose; Duration up to 12 weeks; The treatment was titrated until optimal dosage(that which patient/ caregiver felt that nocturnal hypokinesia and/or early morning akinesia was adequately controlled)(or patient can not tolerated the side effects such as dyskinesia); All previous dopaminergic medications were not allowed to adjusted during the study period.	Drug: Rotigotine; Other Names: Neupro patch
Placebo Comparator: Control (placebo) group; Placebo transdermal patch were titration with the same protocol as active group. Duration up to 12 weeks; The treatment (placebo patch) was titrated until optimal dosage(that which patient/ caregiver felt that nocturnal hypokinesia and/or early morning akinesia was adequately controlled)(or patient can not tolerated the side effects such as dyskinesia); All previous dopaminergic medications were not allowed to adjusted during the study period.	Drug: Placebo; Placebo of rotigotine patch; Other Names: Control group

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Nocturnal parameters from wearable sensors during nighttime	The wearable sensors are the tri-axis accelerometer and gyrometer which will be attached at waist and wrist of patients up to 10 hours. The raw data from wearable sensors will be analyzed by MATLAB program. The results from MATLAB include the number of turning in bed.	up to 10 hours

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Nocturnal Akinesia Dystonia Cramp score (NADCs)	The nocturnal akinesia dystonia cramp score (NADCs) questionnaire was asked before and after participants got the interventions in both active and placebo groups.	Before and after maintenance dosage intervention within 1 month.
PDSS-2	The Parkinson's disease sleep scale- 2 questionnaire was asked before and after participants got the interventions in both active and placebo groups.	Before and after maintenance dosage intervention within 1 month.

Collaborators and Investigators

• Sponsor: Chulalongkorn University
• Collaborators: Abbott

Study record dates

Study Major Dates

• Study Start: September 1, 2016
• Primary Completion (Anticipated): December 1, 2017
• Study Completion (Anticipated): May 1, 2018

Study Registration Dates

• First Submitted: February 13, 2017
• First Submitted That Met QC Criteria: March 27, 2017
• First Posted (Actual): March 31, 2017

Study Record Updates

• Last Update Posted (Actual): March 31, 2017
• Last Update Submitted That Met QC Criteria: March 27, 2017
• Last Verified: February 1, 2017

More Information

Terms related to this study

• Keywords: Parkinson's disease; Nocturnal hypokinesia; Rotigotine transdermal patch
• Additional Relevant MeSH Terms: Nervous System Diseases; Neurologic Manifestations; Dyskinesias; Hypokinesia; Physiological Effects of Drugs; Neurotransmitter Agents; Molecular Mechanisms of Pharmacological Action; Dopamine Agonists; Dopamine Agents; Rotigotine
• Other Study ID Numbers: JSringean